Topical liquid crystalline gel containing lornoxicam/cyclodextrin complex
| dc.Affiliation | October University for modern sciences and Arts (MSA) | |
| dc.contributor.author | Ammar H.O. | |
| dc.contributor.author | Ghorab M. | |
| dc.contributor.author | Mahmoud A.A. | |
| dc.contributor.author | Makram T.S. | |
| dc.contributor.author | Noshi S.H. | |
| dc.contributor.other | Department of Pharmaceutical Technology | |
| dc.contributor.other | National Research Center | |
| dc.contributor.other | Tahreer St. | |
| dc.contributor.other | Dokki | |
| dc.contributor.other | Cairo | |
| dc.contributor.other | Egypt; Department of Pharmaceutics | |
| dc.contributor.other | Faculty of Pharmacy | |
| dc.contributor.other | Cairo University | |
| dc.contributor.other | Cairo | |
| dc.contributor.other | Egypt; Department of Pharmaceutics | |
| dc.contributor.other | Faculty of Pharmacy | |
| dc.contributor.other | October 6th University | |
| dc.contributor.other | Cairo | |
| dc.contributor.other | Egypt; Department of Pharmaceutics | |
| dc.contributor.other | Faculty of Pharmacy | |
| dc.contributor.other | MSA University | |
| dc.contributor.other | Cairo | |
| dc.contributor.other | Egypt | |
| dc.date.accessioned | 2020-01-25T19:58:27Z | |
| dc.date.available | 2020-01-25T19:58:27Z | |
| dc.date.issued | 2012 | |
| dc.description | Scopus | |
| dc.description.abstract | Lornoxicam is a potent analgesic non-steroidal anti-inflammatory drug that can be used topically to relieve pain and to reduce inflammation. The objectives of this study were to improve the therapeutic efficacy of lornoxicam by complexation with cyclodextrins and to formulate it in liquid crystalline gel. Lornoxicam and ?-cyclodextrin (?CD) or hydroxypropyl-?- cyclodextrin (HP?CD) complexes were prepared using the kneaded method in 1:1, 1:2, 1:3 and 1:4 drug:CD molar ratios. Inclusion complexation in aqueous solution and solid state was evaluated by the ultraviolet, phase solubility diagram, differential scanning calorimetry, X-ray diffractometry and Fourier-transform infrared spectroscopy. The stoichiometry for the inclusion complex was found to be 1:2 drug:CD molar ratio as determined from Job's plot. This result was confirmed by the in vitro dissolution studies for the prepared complexes. Among all the prepared complexes, the complex prepared with ?CD in 1:2 drug:CD molar ratio showed highest improvement in drug dissolution and was chosen to be formulated in a topical preparation. For developing liquid crystalline gel, different ratios of Brij 97, glycerol and oils (liquid paraffin, isopropyl myristate and Miglyol � 812) were prepared. The formula composed of Brij 97 and glycerol in 3:1 weight ratio, 10% Miglyol � 812 and 40% water showed higher drug release compared to the other prepared gels. Moreover, this formula showed low ex vivo permeation on excised pigskin thus it could offer high topical effect with low systematic side effects. This formula showed superior anti-inflammatory activity when applied topically on rats' skin after induction of burn compared to that of Feldene � gel. � 2011 Springer Science+Business Media B.V. | en_US |
| dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=51064&tip=sid&clean=0 | |
| dc.identifier.doi | https://doi.org/10.1007/s10847-011-0039-y | |
| dc.identifier.doi | PubMed ID : | |
| dc.identifier.issn | 9230750 | |
| dc.identifier.other | https://doi.org/10.1007/s10847-011-0039-y | |
| dc.identifier.other | PubMed ID : | |
| dc.identifier.uri | https://t.ly/5MRPX | |
| dc.language.iso | English | en_US |
| dc.relation.ispartofseries | Journal of Inclusion Phenomena and Macrocyclic Chemistry | |
| dc.relation.ispartofseries | 73 | |
| dc.subject | Burn | en_US |
| dc.subject | Complexation | en_US |
| dc.subject | Cyclodextrin | en_US |
| dc.subject | Dissolution | en_US |
| dc.subject | Liquid crystalline gel | en_US |
| dc.subject | Lornoxicam | en_US |
| dc.subject | Physiochemical characterization | en_US |
| dc.subject | Topical | en_US |
| dc.title | Topical liquid crystalline gel containing lornoxicam/cyclodextrin complex | en_US |
| dc.type | Article | en_US |
| dcterms.isReferencedBy | Madigan, M.T., Martinko, M., Parter, J., Microbial growth control (2000) Brock Biology of Microorganisms, , T.D. Brock (eds). 9 Prentice Hill Inc USA; Fur, J.R., Fundamentals of immunology (1992) Pharmaceutical Microbiology, pp. 305-331. , W.B. Hugo A.D. Russell (eds). 5 Blackwell Scientific Publications London; (2010) Inflammation, , http://en.wikipedia.org/wiki/Inflammation, Accessed30July2010; Gloster, H.M., Brodland, D.G., The epidemiology of skin cancer (1996) Dermatol. Surg., 22, pp. 217-226. , 10.1016/1076-0512(95)00570-6; Maverakis, E., Miyamura, Y., Bowen, M.P., Correa, G., Ono, Y., Goodarzi, H., Light, including ultraviolet (2010) J. Autoimmun., 34, pp. 247-257. , 10.1016/j.jaut.2009.11.011; Foye, W.O., Thomas, L.L., David, A.W., (1995) Principles of Medicinal Chemistry, p. 335. , 4 Williams and Wilkins USA; Lim, H.W., Thorbecke, G.J., Baer, R.L., Effect of indomethacin on alteration of ATPase-positive Langerhans cell density and cutaneous sunburn reaction induced by ultraviolet-B radiation (1983) J. Invest. Dermatol., 81, pp. 455-458. , 10.1111/1523-1747.ep12522659 1:CAS:528:DyaL3sXlvFSks7g%3D; Bissett, D.L., Chatterjee, R., Hannon, D.P., Photoprotective effect of topical anti-inflammatory agents against ultraviolet radiation-induced chronic skin damage in the hairless mouse (1990) Photodermatol. Photoimmunol. Photomed., 7, pp. 153-158. , 1:CAS:528:DyaK3MXhvVWgsLc%3D; Norholt, S.E., Sindet-Pedersen, S., Larsen, U., Bang, U., Ingerslev, J., Nielsen, O., Hansen, H.J., Ersboll, A.K., Pain control after dental surgery: A double-blind, randomised trial of lornoxicam versus morphine (1996) Pain, 67, pp. 335-343. , 10.1016/0304-3959(96)03126-0 1:STN:280:DyaK2s7gvFKntQ%3D%3D; Staunstrup, H., Ovesen, J., Laesrn, U.T., Elbaek, K., Larsen, U., Kroner, K., Efficacy and tolerability of lornoxicam versus tramadol in postoperative pain (1999) J. Clin. Pharmacol., 39, pp. 834-841. , 10.1177/00912709922008362 1:CAS:528:DC%2BD3cXivFWqsw%3D%3D; Loftsson, T., Jarho, P., Masson, M., Jarvinen, T., Cyclodextrins in drug delivery (2005) Expert. Opin. Drug Deliv., 2, pp. 335-351. , 10.1517/17425247.2.1.335 1:CAS:528:DC%2BD2MXjsFantrY%3D; Magn�sd�ttir, A., M�sson, M., Loftsson, T., Self association and cyclodextrin solubilization of NSAIDs (2002) J. Incl. Phenom. Macroc. Chem. Pharm. Bull., 44, pp. 213-218. , 10.1023/A:1023079322024; Mu?oz-Botella, S., Del Castillo, B., Mart�n, M., Cyclodetrin properties and applications of inclusion complex formation (1995) Ars. Pharm., 36, pp. 187-198; Loftssona, T., Jarvinen, T., Cyclodextrins in ophthalmic drug delivery (1999) Adv. Drug Deliv. Rev., 36, pp. 59-79. , 10.1016/S0169-409X(98)00055-6 1:CAS:528:DyaK1MXksFegug%3D%3D; Pitha, J., Milecki, J., Fales, H., Pannell, L., Uekama, K., Hydroxypropyl-?-cyclodextrin preparation and characterization: Effects on solubility of drugs (1986) Int. J. Pharm., 29, pp. 73-82. , 10.1016/0378-5173(86)90201-2 1:CAS:528:DyaL28XhvFejsbY%3D; Loftsson, T., Brewster, M.E., Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization (1996) J. Pharm. Sci., 85, pp. 1017-1025. , 10.1021/js950534b 1:CAS:528:DyaK28XlsFSrsr4%3D; Irie, T., Uekama, K., Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation (1997) J. Pharm. Sci., 86, pp. 147-162. , 10.1021/js960213f 1:CAS:528:DyaK2sXhtVOgsLY%3D; Thompson, D.O., Cyclodextrins-enabling excipients: Their present and future use in pharmaceuticals (1997) Crit. Rev. Ther. Drug. Carr. Syst., 14, pp. 1-104. , 1:CAS:528:DyaK2sXhtlems7g%3D; Gould, S., Scott, R.C., 2-Hydroxypropyl-?-cyclodextrin (HP-?-CD): A toxicology review (2005) Food Chem. Toxicol., 43, pp. 1451-1459. , 10.1016/j.fct.2005.03.007 1:CAS:528:DC%2BD2MXmt1eiu78%3D; Brewster, M.E., MacKie, C., Lampo, A., Noppe, M., Loftsson, T., The use of solubilizing excipients and approaches to generate toxicology vehicles for contemporary drug pipelines (2007) Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics, pp. 221-256. , P. Augustijns M.E. Brewster (eds). American Association of Pharmaceutical Scientists and Springer New York. 10.1007/978-0-387-69154-1-8; Rajewski, R.A., Stella, V.J., Pharmaceutical applications of cyclodextrins. 2. in vivo drug delivery (1996) J. Pharm. Sci., 85, pp. 1142-1169. , 10.1021/js960075u 1:CAS:528:DyaK28XmtFKgu70%3D; Skjodt, N.M., Davies, N.M., Clinical pharmacokinetics of lornoxicam. A short half-life oxicam (1998) Clin. Pharmacokinet., 34, pp. 421-428. , 10.2165/00003088-199834060-00001 1:CAS:528:DyaK1cXkt1eisr0%3D; Lin, S.Z., Wouessidjewe, D., Poelman, M.C., Duchene, D., In vivo evaluation of indomethacin/cyclodextrin complexes. Gastrointestinal tolerance and dermal anti-inflammatory activity (1994) Int. J. Pharm., 106, pp. 63-67. , 10.1016/0378-5173(94)90276-3 1:CAS:528:DyaK2cXktVSntr8%3D; Sinko, P.J., (2006) Martin's Physical Pharmacy and Pharmaceutical Sciences, pp. 278-279. , 5 Lippincott William's & Wilkins Philadelphia; Higuchi, T., Connors, K.A., (1965) Advances in Analytical Chemistry and Instrumentation, pp. 117-212. , Interscience publishers New York; Uekama, K., Horiuchi, Y., Kikuchi, M., Hirayama, F., Ijitsu, T., Ueno, M., Enhanced dissolution and oral bioavailability of ?-tocopheryl esters by dimethyl-?-cyclodextrin complexation (1988) J. Incl. Phenom., 6, pp. 167-174. , 10.1007/BF00663049 1:CAS:528:DyaL1cXltFGqtrY%3D; Khan, K.A., Rhodes, C.T., Effect of compaction pressure on the dissolution efficiency of some direct compression systems (1972) Pharm. Acta Helv., 47, pp. 594-607; Cs�ka, I., Cs�nyi, E., Zapantis, G., Nagy, E., Feh�r-Kiss, A., Horv�th, G., Blazso, G., Eros, I., In vitro and in vivo percutaneous absorption of topical dosage forms: Case studies (2005) Int. J. Pharm., 291, pp. 11-19. , 10.1016/j.ijpharm.2004.07.038; N�rnberg, E., Friess, S., Poloxamers as structure-determining helping materials for brushable systems. 1. Report: Representation and Kennzeichung of tri-component-system from Poloxamer/paraffin/water (Poloxamere als strukturbestimmende Hilfstoffe f�r streichf�hige Systeme. 1. Mitteilung: Darsellung und Kennzeichung von Drei-Komponentsystemen aus Poloxamer/Paraffin/Wasser) (1990) Pharm. Acta Helv., 65, pp. 105-112; Shah, V.P., Tymes, N.W., Yamamoto, L.A., Skelly, J.P., In vitro dissolution profile of transdermal nitroglycerin patches using paddle method (1986) Int. J. Pharm., 32, pp. 243-250. , 10.1016/0378-5173(86)90185-7 1:CAS:528:DyaL28XlvFOjur0%3D; Caon, T., Costa, A.C.O., De Oliveira, M.A.L., Micke, G.A., Sim�es, C.M.O., Evaluation of the transdermal permeation of different paraben combinations through a pig ear skin model (2010) Int. J. Pharm., 391, pp. 1-6. , 10.1016/j.ijpharm.2010.02.006 1:CAS:528:DC%2BC3cXltFCns70%3D; Escribano, E., Calpena, A.C., Queralt, J., Obach, R., Dom�nech, J., Assessment of diclofenac permeation with different formulations: Anti-inflammatory study of a selected formula (2003) Eur. J. Pharm. Sci., 19, pp. 203-210. , 10.1016/S0928-0987(03)00103-9 1:CAS:528:DC%2BD3sXls1Onu7c%3D; Sev�n, A., �zta, P., Senen, D., Tarimci, N., Kartal, M., Erdogan, B., Effects of polyphenols on skin damage due to ultraviolet A rays: An experimental study on rats (2007) J. Eur. Acad. Dermatol. Venereol., 21, pp. 650-656; Chowdhury, P., Panja, S., Chakravorti, S., Photophysical behaviour of 4-(imidazole-1-yl) phenol and its complexation with beta-cyclodextrin in ground and excited states (2004) Spectrochim. Acta A Mol. Biomol. Spectrosc., 60, pp. 2295-2303. , 10.1016/j.saa.2003.12.003; Loftsson, T., Hreinsdottir, D., Masson, M., Evaluation of cyclodextrin solubilization of drugs (2005) Int. J. Pharm., 302, pp. 18-28. , 10.1016/j.ijpharm.2005.05.042 1:CAS:528:DC%2BD2MXpvVWju7w%3D; Loftsson, T., M�sson, M., Sigurj�nsd�ttir, J.F., Methods to enhance the complexation efficiency of cyclodextrins (1999) STP. Pharma. Sci., 9, pp. 237-242. , 1:CAS:528:DyaK1MXlsleiu7s%3D; Yap, K.L., Liu, X., Thenmozhiyal, J.C., Ho, P.C., Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis (2005) Eur. J. Pharm. Sci., 25, pp. 49-56. , 10.1016/j.ejps.2005.01.021 1:CAS:528:DC%2BD2MXjs1Knu7c%3D; Del Valle, E.M.M., Cyclodextrins and their uses: A review (2004) Process Biochem., 39, pp. 1033-1046. , 10.1016/S0032-9592(03)00258-9; Yuan, C., Jin, Z., Aerobic biodegradability of hydroxypropyl-?-cyclodextrins in soil (2007) J. Incl. Phenom. Macrocycl. Chem., 58, pp. 345-351. , 10.1007/s10847-006-9281-0 1:CAS:528:DC%2BD2sXptl2isL4%3D; Loftsson, T., M�asson, M., Brewster, M.E., Self-association of cyclodextrins and cyclodextrin complexes (2003) J. Pharm. Sci., 93, pp. 1091-1099. , 10.1002/jps.20047; Sigurdsson, H.H., Stefansson, E., Gudmundsd�ttir, E., Eysteinsson, T., Thorsteinsd�ttir, M., Loftsson, T., Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration (2005) J. Contr. Rel., 102, pp. 255-262. , 10.1016/j.jconrel.2004.10.004 1:CAS:528:DC%2BD2MXktVGhsA%3D%3D; Buchi, N.N., Chowdary, K.P.R., Murthy, K.V.R., Satyanarayana, V., Hayman, A.R., Becket, G., Inclusion complexation and dissolution properties of nimesulide and meloxicam-hydroxypropyl-?-cyclodextrin binary systems (2005) J. Incl. Phenom. Macroc. Chem., 53, pp. 103-110. , 10.1007/s10847-005-1676-9; Badr-Eldin, S.M., Elkheshen, S.A., Ghorab, M.M., Inclusion complexes of tadalafil with natural and chemically modified ?-cyclodextrins. I: Preparation and in vitro evaluation (2008) Eur. J. Pharm. Biopharm., 70, pp. 819-827. , 10.1016/j.ejpb.2008.06.024 1:CAS:528:DC%2BD1cXhtlagsL7F; Fernandes, C.M., Teresa, V.M., Veiga, F.J., Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds (2002) Eur. J. Pharm. Sci., 15, pp. 79-88. , 10.1016/S0928-0987(01)00208-1 1:CAS:528:DC%2BD38Xms1Glsg%3D%3D; Kim, K.H., Frank, M.J., Henderson, N.L., Applications of differential scanning calorimetry to the study of solid drug dispersions (1985) J. Pharm. Sci., 74, pp. 283-289. , 10.1002/jps.2600740312 1:CAS:528:DyaL2MXitV2hu7o%3D; Jun, S.W., Kim, M.S., Kim, J.S., Park, H.J., Lee, S., Woo, J.S., Preparation and characterization of simvastatin/hydroxypropyl- ?-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process (2007) Eur. J. Pharm. Biopharm., 66, pp. 413-421. , 10.1016/j.ejpb.2006.11.013 1:CAS:528:DC%2BD2sXlsFKmtbs%3D; Rodr�guez-Tenreiro, C., Alvarez-Lorenzo, C., Concheiro, A., Torres-Labandeira, J.J., Characterization of cyclodextrin-carbopol interactions by DSC and FTIR (2004) J. Therm. Anal. Calorim., 77, pp. 403-411. , 10.1023/B:JTAN.0000038981.30494.f4; Ryan, J.A., Compressed pellet X-ray diffraction monitoring for optimization of crystallinity in lyophilized solids: Imipenem: cilastatin sodium case (1986) J. Pharm. Sci., 75, pp. 805-807. , 10.1002/jps.2600750817 1:CAS:528:DyaL2sXptVSmtw%3D%3D; Veiga, M.D., D�az, P.J., Ahsan, F., Interactions of griseofulvin with cyclodextrins in solid binary systems (1998) J. Pharm. Sci., 87, pp. 891-900. , 10.1021/js970233x 1:CAS:528:DyaK1cXjsl2htLo%3D; Lin, S., Kao, Y., Solid particulates of drug-?-cyclodextrin inclusion complexes directly prepared by a spray-drying technique (1989) Int. J. Pharm., 56, pp. 249-259. , 10.1016/0378-5173(89)90022-7 1:CAS:528:DyaK3cXotl2rsA%3D%3D; Moyano, J., Arias-Blanco, M., Gin�s, J., Giordano, F., Solid-state characterization of dissolution characteristics of gliclazide-?-cyclodextrin inclusion complexes (1997) Int. J. Pharm., 148, pp. 211-217. , 10.1016/S0378-5173(96)04848-X 1:CAS:528:DyaK2sXjtF2hu7Y%3D; Cirri, M., Rangoni, C., Maestrelli, F., Mura, P., Development of fast-dissolving tablets of Flurbiprofen-cyclodextrin complexes (2005) Drug Dev. Ind. Pharm., 31, pp. 697-707. , 10.1080/03639040500253694 1:CAS:528:DC%2BD2MXhtV2gtLfN; Moyano, J.R., Gin�s, J.M., Arias, M.J., Rabasco, A.M., Study of the dissolution characteristics of oxazepam via complexation with ?-cyclodextrin (1995) Int. J. Pharm., 114, pp. 95-102. , 10.1016/0378-5173(94)00220-Y 1:CAS:528:DyaK2MXivVKrtrg%3D; Banker, G.S., Rhodes, C.T., (1990) Modern Pharmaceutics, pp. 857-858. , 2 Marcel Dekker New York; Nesseem, I.D., Formulation and evaluation of itraconazole via liquid crystal for topical delivery system (2001) J. Pharmaceut. Biomed. Anal., 26, pp. 387-399. , 10.1016/S0731-7085(01)00414-9 1:CAS:528:DC%2BD3MXls1eitbo%3D; Makai, M., Cs�nyi, E., N�meth, Z., P�link�s, J., Er�s, I., Structure and drug release of lamellar liquid crystals containing glycerol (2003) Int. J. Pharm., 256, pp. 95-107. , 10.1016/S0378-5173(03)00066-8 1:CAS:528:DC%2BD3sXivVGjsbY%3D; Mittal, K.L., Micellization, solubilization and microemulsions (1976) Micellization, Solubilization and Microemulsions, Vol. 1, pp. 45-54. , L.M. Prince (eds). Plenum Press New York; Elworthy, P.H., Florence, A.T., MacFarlane, C.B., (1986) Solubilization by Surface Active Agents, pp. 63-225. , Chapman & Hall London; Kriwet, K., M�ller-Goymann, C.C., Binary diclofenac diethylamine-water systems: Micelles, vesicles and lyotropic liquid crystals (1993) Eur. J. Pharm. Biopharm., 39, pp. 234-238. , 1:CAS:528:DyaK2cXmtlyhsLY%3D; Engstr�m, S., Cubid phases for studies of drug partition into a lipid bilayers (1999) Eur. J. Pharm. Sci., 8, pp. 243-254. , 10.1016/S0928-0987(99)00012-3; Hadgraft, J., Skin, the final frontier (2001) Int. J. Pharm., 224, pp. 1-18. , 10.1016/S0378-5173(01)00731-1 1:CAS:528:DC%2BD3MXmtVarur8%3D; Barry, B.W., (1983) Dermatologic Formulations: Percutaneous Absorption, pp. 1-233. , Marcel Dekker New York; El-Assasy, A., Soliman, I.I., Farid, S.F., Formulation and bioavailability of tiaprofenic acid suppositories (1997) Bull. Fac. Pharm. Cairo. Univ., 35, pp. 151-157. , 1:CAS:528:DyaK1cXitl2ntw%3D%3D; El-Nabarawi, M.A., Nesseem, D.I., Sleem, A.A., Delivery and analgesic activity of tramadol from semisolid (topical) and solid (rectal) dosage forms (2003) Bull. Fac. Pharm. Cairo. Univ., 41, pp. 25-31. , 1:CAS:528:DC%2BD2cXhtVertbfI; Kreilgaard, M., Influence of microemulsions on cutaneous drug delivery (2002) Adv. Drug Del. Rev., 54, pp. 77-S98. , 10.1016/S0169-409X(02)00116-3 1:CAS:528:DC%2BD38XpsVOhtrg%3D; Kripke, M.L., Immunological effects of ultraviolet radiation (1991) J. Dermatol., 18, pp. 429-433. , 1:STN:280:DyaK387gsFGltA%3D%3D; Elmets, C.A., Bergstresser, P.R., Ultraviolet radiation effects on immune processes (1982) Photochem. Photobiol., 6, pp. 715-719. , 10.1111/j.1751-1097.1982.tb09494.x; Yamawaki, M., Katiyar, S.K., Anderson, C.Y., Tubesing, K.A., Mukhtar, H., Elmets, C.A., Genetic variation in low-dose UV-induced suppression of contact hypersensitivity and in the skin photocarcinogenesis response (1997) J. Invest. Dermatol., 109, pp. 716-721. , 10.1111/1523-1747.ep12340683 1:CAS:528:DyaK1cXitFWjtg%3D%3D; Kripke, M.L., Immunological unresponsiveness induced by ultraviolet radiation (1984) Immunol. Rev., 80, pp. 87-102. , 10.1111/j.1600-065X.1984.tb00496.x 1:STN:280:DyaL2M%2FivFWjuw%3D%3D; Jung, E.G., Photocarcinogenesis in the Skin (1991) J. Dermatol., 18, pp. 1-10. , 1:STN:280:DyaK3M3mvVeksw%3D%3D; Rivas, J.M., Ullrich, S.E., The role of IL-4, IL-10 and TNF-alpha in the immune suppression induced by ultraviolet radiation (1994) J. Leukoc. Biol., 56, pp. 769-775. , 1:CAS:528:DyaK2MXis1Kgt7s%3D; Eberlein-K�nig, B., J�ger, C., Przybilla, B., Ultraviolet B radiation-induced production of interleukin 1alpha and interleukin 6 in human squamous carcinoma cell line is wavelength-dependent and can be inhibited by pharmacological agents (1998) Br. J. Dermatol., 139, pp. 415-421. , 10.1046/j.1365-2133.1998.02404.x; Soter, N.A., Acute effects of ultraviolet radiation on the skin (1990) Semin. Dermatol., 9, pp. 11-15. , 1:STN:280:DyaK3czms1CmsA%3D%3D; Snyder, D.S., Cutaneous effects of topical indomethacin, an inhibitor of prostaglandin synthesis, on UV damaged skin (1975) J. Invest. Dermatol., 64, pp. 322-325. , 10.1111/1523-1747.ep12512265 1:CAS:528:DyaE2MXkslaisb4%3D; Kuwamoto, K., Miyauchi-Hashimoto, H., Tanaka, K., Eguchi, N., Inui, T., Urade, Y., Horio, T., Possible involvement of enhanced prostaglandin E2 production on the photosensitivity in xeroderma pigmentosum group A model mice (2000) J. Invest. Dermatol., 114, pp. 241-246. , 10.1046/j.1523-1747.2000.0883x.x 1:CAS:528:DC%2BD3cXktlWgtLY%3D | |
| dcterms.source | Scopus |